UroGen Pharma to Participate at Upcoming Investor Conferences
2024年2月1日 - 10:00PM
ビジネスワイヤ(英語)
– Guggenheim 6th Annual Biotechnology
Conference –
– Oppenheimer 34th Annual Healthcare Life
Sciences Conference –
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that it will
present at the following investor conferences in February:
Guggenheim 6th Annual Biotechnology Conference – February
7-8, 2024 Fireside Chat: February 8, 2024 at 11:00 AM ET
Format: 1x1 meetings Location: New York, NY Webcast Link:
https://guggenheim.metameetings.net/events/guggenheimbiotech24/sessions/50270-urogen-pharma-ltd/webcast
Oppenheimer 34th Annual Healthcare Life Sciences Conference –
February 13-14, 2024 Presentation: February 13, 2024 at 12:00
PM ET Format: Virtual Webcast Link:
https://wsw.com/webcast/oppenheimer33/register.aspx?conf=oppenheimer33&page=urgn&url=https://wsw.com/webcast/oppenheimer33/urgn/2806968
A webcast from both conferences will also be available via the
Investors section of UroGen’s website, www.urogen.com. A replay of
the webcast will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. Jelmyto®
(mitomycin) for pyelocaliceal solution and investigational
treatment UGN-102 (mitomycin) for intravesical solution are
designed to ablate tumors by non-surgical means. UroGen is
headquartered in Princeton, NJ with operations in Israel. Visit
www.urogen.com to learn more or follow us on Twitter,
@UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240201163986/en/
INVESTOR CONTACT:
Vincent Perrone Senior Director, Investor Relations
vincent.perrone@urogen.com 609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano Director, Corporate Communications
cindy.romano@urogen.com 609-460-3583 ext. 1083
UroGen Pharma (NASDAQ:URGN)
過去 株価チャート
から 4 2024 まで 5 2024
UroGen Pharma (NASDAQ:URGN)
過去 株価チャート
から 5 2023 まで 5 2024